T. Rowe Price Investment Management, Inc.

Position in BDTX — Black Diamond Therapeutics, Inc.

CIK 1897612 BALTIMORE, MD

Position in BDTX

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$22,499,409

-$3,274,626 QoQ

Shares Held

10,563,103

-0.4% QoQ

Ownership

18.4%

of shares outstanding

% of Portfolio

0.02%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Sep 2023

11 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Mar 31, 2026

T. Rowe Price Investment Management, Inc. holds $11,176,949,825 across 48 Biotechnology names. BDTX ranks #36 (0.2% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ALNY	Alnylam Pharmaceuticals, Inc.	5,193,324	$1,718,315,111
2	ASND	Ascendis Pharma A/S	6,162,042	$1,409,443,866
3	CYTK	Cytokinetics Inc	17,523,840	$1,154,996,294
4	APGE	Apogee Therapeutics, Inc.	10,300,984	$867,033,823
5	PCVX	Vaxcyte, Inc.	12,126,017	$704,642,847
6	DYN	Dyne Therapeutics, Inc.	30,785,801	$558,146,572
7	BNTX	BioNTech SE	5,856,073	$520,487,768
8	IONS	Ionis Pharmaceuticals Inc	6,159,027	$462,481,337

12 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$7,452,173	4,028,202	-61.9%	Shares	Sole	2026-07-08
2026-03-31	$22,499,409	10,563,103	-0.4%	Shares	Sole	2026-05-15
2025-12-31	$25,774,035	10,606,599	-1.3%	Shares	Sole	2026-02-19
2025-09-30	$40,720,165	10,744,107	+2.2%	Shares	Sole	2025-11-14
2025-06-30	$26,070,092	10,512,134	+1.1%	Shares	Sole	2025-08-14
2025-03-31	$16,118,823	10,399,241	-0.6%	Shares	Sole	2025-05-14
2024-12-31	$22,398,782	10,466,721	-2.5%	Shares	Sole	2025-02-14
2024-09-30	$46,694,592	10,734,389	+0.7%	Shares	Sole	2024-11-14
2024-06-30	$49,674,341	10,659,730	+58.5%	Shares	Sole	2024-08-14
2024-03-31	$34,097,600	6,725,365	+71.2%	Shares	Sole	2024-05-15
2023-12-31	$11,037,339	3,927,879	+82.4%	Shares	Sole	2024-02-14
2023-09-30	$6,180,797	2,153,588	—	Shares	Sole	2023-11-14
No filing history on record for this holder in this stock.